<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130582</url>
  </required_header>
  <id_info>
    <org_study_id>2015KY143</org_study_id>
    <nct_id>NCT03130582</nct_id>
  </id_info>
  <brief_title>High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT</brief_title>
  <official_title>2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yang Jun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic&#xD;
      stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d&#xD;
      intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48&#xD;
      hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs.&#xD;
      Peripheral blood counts were performed daily for all patients following the initiating of&#xD;
      rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4Ã—109/L&#xD;
      with blood cell The harvested cells reached at least 2*108/kg for mononuclear cells and/or&#xD;
      2*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen&#xD;
      in liquid nitrogen.Auto-PBSCT&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2005</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>10 years</time_frame>
    <description>death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CR</measure>
    <time_frame>10 years</time_frame>
    <description>Complete response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>relapse</measure>
    <time_frame>10 years</time_frame>
    <description>relapse</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">88</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Disease status at mobilization PR</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease status at mobilization PD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high-dose etoposide</intervention_name>
    <description>an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.</description>
    <arm_group_label>Disease status at mobilization PD</arm_group_label>
    <arm_group_label>Disease status at mobilization PR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with refractory/relapsed lymphoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  relapsed/refractory lymphoma ,siut APBSCT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  bone marrow without involvement by lymphoma cells&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 22, 2017</study_first_submitted>
  <study_first_submitted_qc>April 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Yang Jun</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>high-dose etoposide,autologous peripheral blood stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

